Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
Headache: The Journal of Head and Face Pain · 2025-04 · 65 (4) · 589-607
DOI: 10.1111/head.14925 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 14.03.2025. Verfasst von Dawn C Buse und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Disease Progression. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
To estimate rates of migraine progression and assess predictors of progression in a large, longitudinal cohort study using the traditional definition and two alternative definitions of migraine progression.
Background
Traditionally, migraine progression is defined as moving from episodic migraine (EM) with ≤ 14 monthly headache days (MHD) to chronic migraine (CM) with ≥ 15 MHDs of which 8 are attributable to migraine. This definition does not take into account changes in the full range of potential headache days, disability, or impact on function.
Methods
The Observational Survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME) study identified, characterized, and followed a representative sample of adults with migraine in the United States. Migraine was defined based on the International Classification of Headache Disorders, 3rd edition (ICHD‐3) criteria. We estimated rates of migraine progression at 1 year of follow‐up using three definitions: (1) traditional EM‐to‐CM transition, (2) increase of ≥ 5 MHDs (MHD progression), and (3) increase of ≥ 5 points on the Migraine Disability Assessment (MIDAS) scale (MIDAS progression). The analysis identified sociodemographic, clinical, and migraine‐related characteristics associated with each definition of progression from a set of 67 candidates and then determined the association with progression for each candidate predictor and each definition of progression.
Results
A total of 11,634 participants met ICHD‐3 criteria for migraine at baseline and completed the 1‐year follow‐up survey. The average age was 48.2 years, and average years living with migraine was 22.8 years. The sample was 75.6% female (8793/11,634), 84.4% White (9814/11,634), 6.5% Black (757/11,634), and 7.6% Hispanic (889/11,634). The majority (89.2%, 10,374/11,634) had EM at baseline, and among these, 4.7% progressed to CM over 1 year of follow‐up. Rates of progression at 1 year were higher using other definitions of progression, with 9.6% (1087/11,329) reporting an increase in ≥ 5 MHDs and 21.7% (2519/11,630) reporting an increase of ≥ 5 MIDAS points. Across all three definitions of progression, ever taking preventive medications for migraine placed people at lower odds of progressing (odds ratio [95% confidence interval]: EM‐to‐CM transition, 0.7 [0.57–0.85]; MHD progression, 0.9 [0.75–1.00]; MIDAS progression, 0.8 [0.73–0.91]), while the presence of depression placed people at higher odds of progressing (odds ratio [95% confidence interval]: EM‐to‐CM transition, 1.3 [1.05–1.69]; MHD progression, 1.4 [1.21–1.67]; MIDAS progression, 1.2 [1.04–1.34]).
Conclusion
This work expands the concept of migraine progression, exploring two alternative definitions that modify the potential range of MHD changes and take disability into account. This analysis identified never having used preventive medications for migraine and presence of depression as risk factors across all three definitions of progression. This work may more accurately identify persons with progression and at risk of migraine progression, setting the stage for trials of preventive intervention and ultimately more effective practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Department of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
- Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Montefiore Headache Center, Bronx, New York, USA.
ORCID-Profile: Sait Ashina, Robert A Nicholson, Richard B Lipton
Förderung
- Eli Lilly and Company
Zitieren
APA
Buse, D. C., Muenzel, E. J., Zagar, A. J., Mehrabadi, A. S., Shapiro, R. E., Kim, G., Ashina, S., Nicholson, R. A., & Lipton, R. B. (2025). Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study. Headache: The Journal of Head and Face Pain, 65(4), 589-607. https://doi.org/10.1111/head.14925
Vancouver
Buse DC, Muenzel EJ, Zagar AJ, Mehrabadi AS, Shapiro RE, Kim G, et al. Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study. Headache: The Journal of Head and Face Pain. 2025;65(4):589-607. doi:10.1111/head.14925
BibTeX
@article{Buse2025,
author = {Buse, Dawn C and Muenzel, E Jolanda and Zagar, Anthony J and Mehrabadi, Ali Sheikhi and Shapiro, Robert E and Kim, Gilwan and Ashina, Sait and Nicholson, Robert A and Lipton, Richard B},
title = {Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
volume = {65},
number = {4},
pages = {589--607},
doi = {10.1111/head.14925}
}
EUVIMED